Method for preparing 1-aryl-3-arylamino-2-pyrazolin-5-ones from
N-aryl-3-arylamino-3-oximinopropionamides
    91.
    发明授权
    Method for preparing 1-aryl-3-arylamino-2-pyrazolin-5-ones from N-aryl-3-arylamino-3-oximinopropionamides 失效
    从N-芳基-3-芳基氨基-3-肟基丙酰胺制备1-芳基-3-芳基氨基-2-吡唑啉-5-酮的方法

    公开(公告)号:US4374253A

    公开(公告)日:1983-02-15

    申请号:US306622

    申请日:1981-09-28

    IPC分类号: C07B61/00 C07D231/52

    CPC分类号: C07D231/52

    摘要: A method for preparing a 1-aryl-3-arylamino-2-pyrazolin-5-one comprises reacting an N-aryl-3-arylamino-3-oximinopropionamide with an acylating agent in an inert solvent, then heating in contact with a strong acid catalyst and a dehydrating agent in an inert solvent, and then heating in contact with an acid in water and a lower alkanol.

    摘要翻译: 制备1-芳基-3-芳基氨基-2-吡唑啉-5-酮的方法包括在惰性溶剂中使N-芳基-3-芳基氨基-3-肟基丙酰胺与酰化剂反应,然后与强烈的 酸催化剂和脱水剂在惰性溶剂中,然后加热与酸在水和低级链烷醇中接触。

    Color photographic light-sensitive element
    92.
    发明授权
    Color photographic light-sensitive element 失效
    彩色摄影感光元件

    公开(公告)号:US4336325A

    公开(公告)日:1982-06-22

    申请号:US199125

    申请日:1980-10-22

    CPC分类号: G03C7/384 C07D231/52

    摘要: A color photographic light-sensitive element comprising a support having thereon a silver halide emulsion layer containing therein a 3-anilino-5-pyrazolone magenta-color-forming coupler represented by the following general formula (I): ##STR1## wherein ##STR2## (an N-substituted acylamino group) is present at the 4- or 5-position of the anilino group; R.sub.1 represents a substituted or unsubstituted alkyl group, an alkenyl group, a cycloalkyl group, a cycloalkyl, a cycloalkenyl group or an aralkyl group; R.sub.2 represents an aliphatic hydrocarbon group, a heterocyclic group or an aryl group; X represents a halogen atom or an alkoxy group; Z represents hydrogen or a coupling-off group; and Ar represents an aryl group.The 3-anilino-5-pyrazolone magenta-color-forming coupler is useful in preventing the formation of yellow stain due to light irradiation in unexposed areas of a color photographic light-sensitive element after color development processing.

    摘要翻译: 一种彩色摄影感光元件,包括其上具有卤化银乳剂层的载体,其中含有由以下通式(I)表示的3-苯胺基-5-吡唑啉酮品红色形成成色剂:其中 苯胺基的4-或5-位存在(N-取代的酰基氨基) R1表示取代或未取代的烷基,烯基,环烷基,环烷基,环烯基或芳烷基; R2表示脂族烃基,杂环基或芳基; X表示卤素原子或烷氧基; Z表示氢或偶联离去基团; Ar表示芳基。 3-苯胺基-5-吡唑啉酮品红色成色剂可用于防止由于在显色处理后的彩色照相感光元件的未曝光区域中的光照射而形成黄色斑点。

    Process and material for forming color photographic image
    93.
    发明授权
    Process and material for forming color photographic image 失效
    用于形成彩色摄影图像的工艺和材料

    公开(公告)号:US4308343A

    公开(公告)日:1981-12-29

    申请号:US184453

    申请日:1980-09-05

    CPC分类号: G03C7/384 C07D231/52

    摘要: A process for forming a color photographic image comprising processing a silver halide color photographic light-sensitive material in the presence of a magenta coupler represented by the formula (I) ##STR1## wherein R represents an acylamino group, an anilino group or a ureido group; Ar represents a substituted or unsubstituted aryl group; X represents a non-metallic divalent group forming a saturated or unsaturated 5-membered or 6-membered heterocyclic ring together with the nitrogen atom; and Y represents an acyl group or a sulfonyl group.The 2-equivalent magenta coupler represented by the formula (I) is stable to chemicals and has a good solubility to an organic solvent which is employed to incorporate couplers into a photographic light-sensitive material. A photographic light-sensitive material comprising a support having thereon at least one silver halide emulsion layer containing the 2-equivalent magenta coupler represented by the formula (I) is also disclosed.

    摘要翻译: 一种用于形成彩色照相图像的方法,包括在式(I)表示的品红色偶联剂存在下处理卤化银彩色照相感光材料,其中R表示酰氨基,苯胺基或 脲基; Ar表示取代或未取代的芳基; X表示与氮原子一起形成饱和或不饱和的5元或6元杂环的非金属二价基团; Y表示酰基或磺酰基。 由式(I)表示的2-当量的品红成色剂对于化学品是稳定的,并且对有机溶剂具有良好的溶解性,该有机溶剂用于将成色剂掺入照相感光材料中。 还公开了一种照相感光材料,其包含其上具有至少一个含有由式(I)表示的2-等价品红成色剂的卤化银乳剂层的载体。

    Pyrazol-5-ones
    95.
    再颁专利
    Pyrazol-5-ones 失效
    吡唑-5-酮

    公开(公告)号:USRE30420E

    公开(公告)日:1980-10-21

    申请号:US765666

    申请日:1977-02-04

    摘要: 1-Substituted pyrazole-5-ones of the formula ##STR1## and pharmaceutically acceptable, nontoxic salts thereof, wherein R is hydrogen or amino;R.sup.1 is hydrogen, alkyl, alkenyl, unsubstituted or substituted aryl or unsubstituted or substituted aralky;X isa. ethylene, ethylene wherein 1 hydrogen atom on one of the carbon atoms is substituted by alkyl of 1 to 4 carbon atoms, ethylene wherein 1 hydrogen atom on each of the two carbon atoms is substituted by alkyl of 1 to 4 carbon atoms or said ethylene which is linked to R.sup.2 via an oxygen or sulphur atom;b. propenyl, propenyl wherein 1 hydrogen atom on one, two or three of the carbon atoms is substituted by alkyl of 1 to 4 carbon atoms, said propenyl being linked to the N.sup.1 atom of the pyrazol ring via its methylene moiety; orc. methylene;provided that when X is methylene, R.sup.1 is not hydrogen if R is amino;R.sup.2 is aryl unsubstituted or substituted by:a. 1 or 2 of the same or different substituents selected from the group consisting of halogen, trifluoromethyl, alkyl of 1 to 8 carbon atoms, alkenyl of 2 to 8 carbon atoms, and lower alkoxy;b. cycloalkyl of 5, 6 or 7 carbon atoms or cycloalkenyl of 5, 6 or 7 carbon atoms;c. alkylamino, dialkylamino, cyano, trifluoromethoxy, nitro, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, or said carbamoyl wherein the nitrogen atom is a member of a heterocyclic ring, sulphamyl, alkylsulphamyl, dialkylsulphamyl, or said sulphamyl wherein the nitrogen is a member of a heterocyclic ring, or --SO.sub.n alkyl wherein n is 0, 1 or 2;d. alkylamino, dialkylamino, cyano, trifluoromethoxy, nitro, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, or said carbamoyl wherein the nitrogen atom is a member of a heterocyclic ring, sulphamyl, alkylsulphamyl, dialkylsulphamyl or said sulphamyl wherein the nitrogen is a member of a heterocyclic ring, or --SO.sub.n -- alkyl wherein n is 0, 1 or 2, and 1 or 2 of the same or different substituents selected from the group consisting of alkyl, alkenyl, alkoxy, halogen, and trifluoromethyl; ore. a fused, saturated or unsaturated 5-, 6-, or 7-membered ring or said ring containing 1 or 2 oxygen or sulphur atoms;are useful for their diuretic, saluretic, antihypertensive and antithrombotic effects.

    Process for the production of 3-substituted amino-5-pyrazolones
    96.
    发明授权
    Process for the production of 3-substituted amino-5-pyrazolones 失效
    制备3-取代的氨基-5-吡唑啉酮的方法

    公开(公告)号:US4188489A

    公开(公告)日:1980-02-12

    申请号:US677452

    申请日:1976-04-16

    摘要: 3-Substituted amino-5-pyrazolones containing at least one sulfo group represented by the formula: ##STR1## and a process for producing the above pyrazolones by reacting a .beta.-substituted amino-.beta.-alkoxy acrylic acid derivative represented by the formula: ##STR2## and a hydrazine containing at least one sulfo group represented by the formula:NH.sub.2 --NH--Qwherein R.sup.1 is a hydrogen atom, an aliphatic group, an aralkyl group or an aryl group; R.sup.2 is an aliphatic group, an aralkyl group, a heterocyclic group, an aryl group or an acyl group; l is 0 or 1 and where l is O, R.sup.1 and R.sup.2 may combine with each other to form an alkylene group or an alkylene group interrupted by a hetero atom; R.sup.3 is an aliphatic group or an aralkyl group; X is oxygen or sulfur; Y is a hydroxy group, an alkoxy group, an aralkoxy group, or a primary, secondary or tertiary amino group; and Q is an aliphatic group, an aryl group, or an aralkyl group containing at least one sulfo group.

    摘要翻译: 3-取代的含有至少一个由下式表示的磺基的氨基-5-吡唑啉酮:通过使由下式表示的β-取代的氨基-β-烷氧基丙烯酸衍生物与下式反应制备上述吡唑啉酮的方法: IMAGE>和含有由式NH 2 -NH-Q表示的至少一个磺基的肼,其中R1是氢原子,脂族基团,芳烷基或芳基; R2是脂族基团,芳烷基,杂环基,芳基或酰基; l为0或1,其中l为O,R1和R2可以相互结合形成亚烷基或被杂原子间隔的亚烷基; R3是脂族基团或芳烷基; X是氧或硫; Y是羟基,烷氧基,芳烷氧基或伯,仲或叔氨基; Q为含有至少一个磺基的脂族基团,芳基或芳烷基。

    Pyrazol-5-ones
    98.
    发明授权
    Pyrazol-5-ones 失效
    吡唑-5-酮

    公开(公告)号:US3992404A

    公开(公告)日:1976-11-16

    申请号:US578516

    申请日:1975-05-19

    摘要: 1-Substituted pyrazole-5-ones of the formula ##SPC1##And pharmaceutically acceptable, nontoxic salts thereof, whereinR is hydrogen or amino;R.sup.1 is hydrogen, alkyl, alkenyl, unsubstituted or substituted aryl or unsubstituted or substituted aralky;X isA. ethylene, ethylene wherein 1 hydrogen atom on one of the carbon atoms is substituted by alkyl of 1 to 4 carbon atoms, ethylene wherein 1 hydrogen atom on each of the two carbon atoms is substituted by alkyl of 1 to 4 carbon atoms or said ethylene which is linked to R.sup.2 via an oxygen or sulphur atom;B. propenyl, propenyl wherein 1 hydrogen atom on one, two or three of the carbon atoms is substituted by alkyl of 1 to 4 carbon atoms, said propenyl being linked to the N.sup.1 atom of the pyrazol ring via its methylene moiety; orC. methylene;Provided that when X is methylene, R.sup.1 is not hydrogen if R is amino;R.sup.2 is aryl unsubstituted or substituted by:A. 1 or 2 of the same or different substituents selected from the group consisting of halogen, trifluoromethyl, alkyl of 1 to 8 carbon atoms, alkenyl of 2 to 8 carbon atoms and lower alkoxy;B. cycloalkyl of 5, 6 or 7 carbon atoms of cycloalkenyl of 5, 6 or 7 carbon atoms,C. alkylamino, dialkylamino, cyano, trifluoromethoxy, nitro, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, or said carbamoyl wherein the nitrogen atom is a member of a heterocyclic ring, sulphamyl, alkylsulphamyl, dialkylsulphamyl, or said sulphamyl wherein the nitrogen is a member of a heterocyclic ring, or --SO.sub.n alkyl wherein n is 0, 1 or 2;D. alkylamino, dialkylamino, cyano, trifluoromethoxy, nitro, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, or said carbamoyl wherein the nitrogen atom is a member of a heterocyclic ring, sulphamyl, alkylsulphamyl, dialkylsulphamyl or said sulphamyl wherein the nitrogen is a member of a heterocyclic ring, or --SO.sub.n -- alkyl wherein n is 0, 1 or 2, and 1 or 2 of the same or different substituents selected from the group consisting of alkyl, alkenyl, alkoxy, halogen, and trifluoromethyl; orE. a fused, saturated or unsaturated 5-, 6-, or 7-membered ring or said ring containing 1 or 2 oxygen or sulphur atoms;Are useful for their diuretic, saluretic, antihypertensive and antithrombotic effects.

    摘要翻译: 1-取代的吡唑-5-,式+ q,10和药物可接受的,其非阳离子盐,其中R是氢或氨基; R1是氢,烷基,烯基,未取代或取代的芳基或未取代或取代的芳基; X是A.乙烯,其中一个碳原子上的1个氢原子的1个氢原子是由1至4个碳原子的烷基取代的,在两个碳原子上的1个氢原子被1至4个碳原子的烷基取代的乙烯 或通过氧或硫原子与R2连接的乙烯; B.丙烯,丙烯,其中1个氢原子在一个碳原子上,两个或三个碳原子被1至4个碳原子的烷基取代,通过其亚甲基部分连接到吡唑环的N1原子上。 或C. METHYLENE; 当X是亚甲基时,如果R是氨基,则R1不是氢; R2是未取代的或被下列基团取代的芳基: